QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis

被引：0

作者：

Peyrin-Biroulet, L. ^{[1
]}

Rubin, D. ^{[2
]}

Lichtenstein, G. ^{[3
]}

Shipitofsky, N. ^{[4
]}

Huang, K. H. ^{[4
]}

Germinaro, M. ^{[4
]}

Wilson, R. ^{[5
]}

Zhang, H. ^{[5
]}

DuVall, G. A. ^{[6
]}

Cao, Q. ^{[7
]}

Allegretti, J. ^{[8
]}

Feagan, B. ^{[9
]}

Hisamatsu, T. ^{[10
]}

Panes, J. ^{[11
]}

Dignass, A. ^{[12
]}

Bressler, B. ^{[13
]}

Sands, B. ^{[14
]}

机构：

[1] Nancy Univ Hosp, Gastroenterol, Nancy, France

[2] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA

[3] Univ Pennsylvania, Dept Med, Div Gastroenterol, Raymond & Ruth Perelman Sch, Philadelphia, PA USA

[4] Janssen Res Dev LLC, Immunol, Spring House, PA USA

[5] anssen Res Dev LLC, Biostat, Spring House, PA USA

[6] Tyler Res Inst LLC, Gastroenterol, Tyler, TX USA

[7] Zhejiang Univ, Sch Med, Hangzhou, Peoples R China

[8] Brigham & Womens Hosp, Crohns & Colitis Ctr, Gastroenterol Hepatol & Endoscopy, Boston, MA USA

[9] Alimentiv Inc, Gastroenterol, London, ON, Canada

[10] Kyorin Univ, Gastroenterol & Hepatol, Tokyo, Japan

[11] CIBERehd, Gastroenterol, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[12] Agaples Markus Hosp, Dept Med, Frankfurt, Germany

[13] Univ British Columbia, Div Gastroenterol, Vancouver, BC, Canada

[14] Icahn Sch Med Mt Sinai, Dr Henry Janowitz Div Gastroenterol, New York, NY USA

来源：

JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P493

引用

页码：624 / 625

页数：3

共 50 条

[21] Guselkumab: A New Therapeutic Option for the Treatment of Moderately to Severely Active Ulcerative Colitis
Bhat, Shubha
Choi, David
ANNALS OF PHARMACOTHERAPY, 2025,
[22] Guselkumab improves health-related quality of life as measured by PROMIS-29 in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study
Panes, J.
Dignass, A.
Lichtenstein, G.
Huang, K. H.
Germinaro, M.
Houck, N.
Han, C.
Miao, Y.
Zhang, H.
Abu Farsakh, N.
Patel, B.
Owczarek, D.
Hisamatsu, T.
Sands, B.
Bressler, B.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I160 - I161
[23] Improvement in Inflammatory Biomarker Levels Through Week 12 in Moderately to Severely Active Ulcerative Colitis Patients Treated With Guselkumab: Results From the Phase 3 QUASAR Induction Study
Hisamatsu, Tadakazu
Peyrin-Biroulet, Laurent
Dignass, Axel
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Houck, Nicole
Miao, Ye
Zhang, Hongyan
Argollo, Marjorie
Takeuchi, Ken
Filip, Rafal
Allegretti, Jessica R.
Feagan, Brian G.
Sands, Bruce E.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S810 - S810
[24] The Effect of Guselkumab Induction Therapy on Inflammatory Biomarkers in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results Through Week 12
Lichtenstein, Gary
Dignass, Axel
Sandborn, William J.
Huang, Kuan-Hsiang
Germinaro, Matthew
Wilson, Rebbecca
Zhang, Hongyan
Chen, Baili
Chen, Minhu
Hisamatsu, Tadakazu
Feagan, Brian G.
Panes, Julian
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S587 - S587
[25] Impact of Guselkumab Therapy on Histologic and Combined Histologic and Endoscopic Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Week 12 Results From the Phase 3 QUASAR Induction Study
Panes, Julian
Sands, Bruce E.
Peyrin-Biroulet, Laurent
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Sridhar, Sunandini
Branigan, Patrick
Miao, Ye
Zhang, Hongyan
Hebuterne, Xavier
Gyokeres, Tibor
Hirai, Fumihito
Hisamatsu, Tadakazu
Rubin, David T.
Feagan, Brian G.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S874 - S875
[26] Guselkumab induction restores intestinal immune homeostasis and promotes epithelial repair in moderately to severely active Ulcerative Colitis
Sridhar, S.
Hart, A.
Venkat, S.
Ruane, D.
Horowitz, D.
Lee, T.
Waterworth, D.
Huang, K. H. G.
Germinaro, M.
Vetter, M.
Cua, D.
Freeman, T. C.
Sisk, C.
McRae, B.
Verstockt, B.
Rubin, D. T.
Sands, B. E.
Branigan, P.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I41 - I41
[27] GUSELKUMAB INDUCTION RESTORES INTESTINAL IMMUNE HOMEOSTASIS AND PROMOTES EPITHELIAL REPAIR IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Sridhar, Sunan
Hart, Amy
Venkat, Swati
Ruane, Darren
Horowitz, Dan
Lee, Tae
Waterworth, Dawn M.
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Vetter, Marion
Cua, Daniel
Freeman, Tom C.
Sisk, Christopher
Mcrae, Bradford
Verstockt, Bram
Rubin, David T.
Sands, Bruce E.
Branigan, Patrick
GASTROENTEROLOGY, 2024, 166 (05) : S790 - S790
[28] Guselkumab maintenance treatment improves health-related quality of life in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR maintenance study
Bressler, B.
Peyrin-Biroulet, L.
Afif, W.
Samaan, M. A.
Wei, S. C.
Yarandi, S.
Germinaro, M.
Mistry, P.
Han, C.
Allegretti, J. R.
Lichtenstein, G. R.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2133 - i2135
[29] EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
D'Haens, Geert
Higgins, Peter D.
Peyrin-Biroulet, Laurent
Sands, Bruce E.
Lee, Scott
Moses, Richard
Redondo, Isabel
Escobar, Rodrigo
Morris, Nathan
Kobayashi, Taku
GASTROENTEROLOGY, 2023, 164 (06) : S1086 - S1086
[30] Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
D'Haens, G.
Higgins, P. D. R.
Peyrin-Biroulet, L.
Sands, B. E.
Lee, S.
Moses, R. E.
Redondo, I.
Escobar, R.
Morris, N.
Kobayashi, T.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 682 - 682

← 1 2 3 4 5 →